Literature DB >> 26405579

A clinical trial of multiple peptides vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS.

Yoshihiro Yoshitake1, Yasuharu Nishimura2, Yusuke Nakamura3, Masanori Shinohara1.   

Abstract

A phase II clinical trial for head and neck squamous cell cancer (HNSCC) patients using multiple peptides vaccine derived from tumor-associated antigens (TAAs) was performed. The therapy was well tolerated and overall survival was statistically significantly longer in vaccinated patients, and the patients exhibiting cytotoxic T lymphocytes (CTL) responses to multiple peptides exhibited better prognosis.

Entities:  

Keywords:  cancer vaccine therapy; cytotoxic T lymphocytes; head and neck squamous cell cancer; multiple peptides vaccine; phase II clinical trial; tumor-associated antigens

Year:  2015        PMID： 26405579      PMCID： PMC4570101          DOI： 10.1080/2162402X.2015.1022307

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum.

Authors:  David M Brizel; Ramon Esclamado
Journal:  J Clin Oncol       Date:  2006-06-10       Impact factor: 44.544

2.  Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.

Authors:  Yoshihiro Yoshitake; Daiki Fukuma; Akira Yuno; Masatoshi Hirayama; Hideki Nakayama; Takuya Tanaka; Masashi Nagata; Yasuo Takamune; Kenta Kawahara; Yoshihiro Nakagawa; Ryoji Yoshida; Akiyuki Hirosue; Hidenao Ogi; Akimitsu Hiraki; Hirofumi Jono; Akinobu Hamada; Koji Yoshida; Yasuharu Nishimura; Yusuke Nakamura; Masanori Shinohara
Journal:  Clin Cancer Res       Date:  2014-11-12       Impact factor: 12.531

3.  Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas.

Authors:  Takumi Yamabuki; Yataro Daigo; Tatsuya Kato; Satoshi Hayama; Tatsuhiko Tsunoda; Masaki Miyamoto; Tomoo Ito; Masahiro Fujita; Masao Hosokawa; Satoshi Kondo; Yusuke Nakamura
Journal:  Int J Oncol       Date:  2006-06       Impact factor: 5.650

4.  Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer.

Authors:  Koji Kono; Yoshiki Mizukami; Yataro Daigo; Atsushi Takano; Ken Masuda; Koji Yoshida; Takuya Tsunoda; Yoshihiko Kawaguchi; Yusuke Nakamura; Hideki Fujii
Journal:  Cancer Sci       Date:  2009-05-14       Impact factor: 6.716

Review 5.  Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

Authors:  Ulrich Keilholz; Jeffrey Weber; James H Finke; Dmitry I Gabrilovich; W Martin Kast; Mary L Disis; John M Kirkwood; Carmen Scheibenbogen; Jeff Schlom; Vernon C Maino; H Kim Lyerly; Peter P Lee; Walter Storkus; Franceso Marincola; Alexandra Worobec; Michael B Atkins
Journal:  J Immunother       Date:  2002 Mar-Apr       Impact factor: 4.456

6.  Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy.

Authors:  Takako Suda; Takuya Tsunoda; Yataro Daigo; Yusuke Nakamura; Hideaki Tahara
Journal:  Cancer Sci       Date:  2007-11       Impact factor: 6.716

7.  Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients.

Authors:  Yusuke Tomita; Akira Yuno; Hirotake Tsukamoto; Satoru Senju; Sachiko Yoshimura; Ryuji Osawa; Yasuhiro Kuroda; Masatoshi Hirayama; Atsushi Irie; Akinobu Hamada; Hirofumi Jono; Koji Yoshida; Takuya Tsunoda; Hirotsugu Kohrogi; Yoshihiro Yoshitake; Yusuke Nakamura; Masanori Shinohara; Yasuharu Nishimura
Journal:  Int J Cancer       Date:  2014-01-15       Impact factor: 7.396

8.  Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas.

Authors:  Nobuhisa Ishikawa; Atsushi Takano; Wataru Yasui; Kouki Inai; Hitoshi Nishimura; Hiroyuki Ito; Yohei Miyagi; Haruhiko Nakayama; Masahiro Fujita; Masao Hosokawa; Eiju Tsuchiya; Nobuoki Kohno; Yusuke Nakamura; Yataro Daigo
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

9.  Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.

Authors:  Koji Kono; Hisae Iinuma; Yasunori Akutsu; Hiroaki Tanaka; Naoko Hayashi; Yasuto Uchikado; Tsuyoshi Noguchi; Hideki Fujii; Kota Okinaka; Ryoji Fukushima; Hisahiro Matsubara; Masaichi Ohira; Hideo Baba; Shoji Natsugoe; Seigou Kitano; Kazuyoshi Takeda; Koji Yoshida; Takuya Tsunoda; Yusuke Nakamura
Journal:  J Transl Med       Date:  2012-07-09       Impact factor: 5.531

10.  Identification of immunogenic LY6K long peptide encompassing both CD4+ and CD8+ T-cell epitopes and eliciting CD4+ T-cell immunity in patients with malignant disease.

Authors:  Yusuke Tomita; Akira Yuno; Hirotake Tsukamoto; Satoru Senju; Yasuhiro Kuroda; Masatoshi Hirayama; Yuya Imamura; Junji Yatsuda; Mohammad Abu Sayem; Atsushi Irie; Akinobu Hamada; Hirofumi Jono; Koji Yoshida; Takuya Tsunoda; Yataro Daigo; Hirotsugu Kohrogi; Yoshihiro Yoshitake; Yusuke Nakamura; Masanori Shinohara; Yasuharu Nishimura
Journal:  Oncoimmunology       Date:  2014-03-27       Impact factor: 8.110
  10 in total
  4 in total

1.  Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design.

Authors:  Martin G Klatt; Daniel J Kowalewski; Heiko Schuster; Moreno Di Marco; Jörg Hennenlotter; Arnulf Stenzl; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Oncoimmunology       Date:  2016-06-30       Impact factor: 8.110

2.  Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer.

Authors:  Yoshitaro Shindo; Shoichi Hazama; Nobuaki Suzuki; Haruo Iguchi; Kazuhiro Uesugi; Hiroaki Tanaka; Atsushi Aruga; Takashi Hatori; Hidenobu Ishizaki; Yuzo Umeda; Toshiyoshi Fujiwara; Tetsuya Ikemoto; Mitsuo Shimada; Kazuhiko Yoshimatsu; Hiroko Takenouchi; Hiroto Matsui; Shinsuke Kanekiyo; Michihisa Iida; Yasunobu Koki; Hideki Arima; Hiroyuki Furukawa; Tomio Ueno; Shigefumi Yoshino; Tomonobu Fujita; Yutaka Kawakami; Yusuke Nakamura; Masaaki Oka; Hiroaki Nagano
Journal:  J Exp Clin Cancer Res       Date:  2017-02-28

Review 3.  Current Strategies to Enhance Anti-Tumour Immunity.

Authors:  Katherine W Cook; Lindy G Durrant; Victoria A Brentville
Journal:  Biomedicines       Date:  2018-03-23

4.  Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2].

Authors:  Satoshi Takeuchi; Masahiro Kagabu; Tadahiro Shoji; Yukari Nitta; Toru Sugiyama; Junya Sato; Yusuke Nakamura
Journal:  Oncoimmunology       Date:  2020-11-11       Impact factor: 8.110
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.